BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16253877)

  • 1. Biology calls the targets: combining RNAi and disease biology.
    van Es HH; Arts GJ
    Drug Discov Today; 2005 Oct; 10(20):1385-91. PubMed ID: 16253877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can cell systems biology rescue drug discovery?
    Butcher EC
    Nat Rev Drug Discov; 2005 Jun; 4(6):461-7. PubMed ID: 15915152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rational approach to maximize success rate in target discovery.
    Schneider M
    Arch Pharm (Weinheim); 2004 Dec; 337(12):625-33. PubMed ID: 15597396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense and RNAi: powerful tools in drug target discovery and validation.
    Lavery KS; King TH
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets.
    Hardy LW; Peet NP
    Drug Discov Today; 2004 Feb; 9(3):117-26. PubMed ID: 14960389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of RNA interference against cancer.
    Takeshita F; Ochiya T
    Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systems biology in drug discovery.
    Butcher EC; Berg EL; Kunkel EJ
    Nat Biotechnol; 2004 Oct; 22(10):1253-9. PubMed ID: 15470465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How will RNAi facilitate drug development?
    Bartz S; Jackson AL
    Sci STKE; 2005 Aug; 2005(295):pe39. PubMed ID: 16077085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference screening for the discovery of oncology targets.
    Quon K; Kassner PD
    Expert Opin Ther Targets; 2009 Sep; 13(9):1027-35. PubMed ID: 19650760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens.
    Perrimon N; Friedman A; Mathey-Prevot B; Eggert US
    Drug Discov Today; 2007 Jan; 12(1-2):28-33. PubMed ID: 17198970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNAi and high-content screening in target identification and validation.
    Haney SA
    IDrugs; 2005 Dec; 8(12):997-1001. PubMed ID: 16320133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects of RNA interference therapy for cancer.
    Pai SI; Lin YY; Macaes B; Meneshian A; Hung CF; Wu TC
    Gene Ther; 2006 Mar; 13(6):464-77. PubMed ID: 16341059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commercial potential of RNAi.
    Jain KK
    Mol Biosyst; 2006 Nov; 2(11):523-6. PubMed ID: 17216033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short interfering RNA (siRNA): tool or therapeutic?
    Cejka D; Losert D; Wacheck V
    Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. siRNAs in drug discovery: target validation and beyond.
    Natt F
    Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
    Singh SK; Hajeri PB
    Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference in pain research.
    Röhl T; Kurreck J
    J Neurochem; 2006 Oct; 99(2):371-80. PubMed ID: 17029593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA interference as potential therapy for neurodegenerative disease: applications to inclusion-body myositis?
    Paulson H
    Neurology; 2006 Jan; 66(2 Suppl 1):S114-7. PubMed ID: 16432138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.